Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum

American Journal of Infection Control

Volumn 34, Issue 5 SUPPL., 2006, Pages

  McGowan Jr , John E ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BURKHOLDERIA CEPACIA; CENTRAL NERVOUS SYSTEM INFECTION; COST BENEFIT ANALYSIS; CROSS RESISTANCE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MEDICAL PRACTICE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; SEROPREVALENCE; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; UNSPECIFIED SIDE EFFECT;

CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GAMMAPROTEOBACTERIA; GRAM-NEGATIVE AEROBIC RODS AND COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33745263063     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2006.05.226     Document Type: Article

References (62)

1. Saiman L., and Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 17 (2004) 57-71
2. Jones A.M., Dodd M.E., Govan J.R., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 59 (2004) 948-951
3. Quinn J.P. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 27 suppl 1 (1998) S117-S124
4. Vidal F., Mensa J., Almela M., et al. Bacteraemia in adults due to glucose non-fermentative gram-negative bacilli other than P. aeruginosa. QJM 96 (2003) 227-234
5. Hauser A.R., and Sriram P. Severe Pseudomonas aeruginosa infections. Tackling the conundrum of drug resistance. Postgrad Med 117 (2005) 41-48
6. Hancock R.E., and Speert D.P. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat 3 (2000) 247-255
7. Gaynes R., and Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41 (2005) 848-854
8. Quale J., Bratu S., Landman D., and Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 37 (2003) 214-220
9. Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 53 (2004) 1063-1066
10. Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., and Sahm D.F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47 (2003) 1681-1688
11. Streit J.M., Jones R.N., Sader H.S., and Fritsche T.R. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 24 (2004) 111-118
12. Hoban D.J., Biedenbach D.J., Mutnick A.H., and Jones R.N. Pathogens of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 45 (2003) 279-285
13. Rennie R.P., Jones R.N., and Mutnick A.H. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 45 (2003) 287-293
14. Fridkin S.K., and Gaynes R.P. Antimicrobial resistance in intensive care units. Clin Chest Med 20 (1999) 303-316 viii
15. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
16. Bratu S., Quale J., Cebular S., Heddurshetti R., and Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 24 (2005) 196-201
17. Andrade S.S., Jones R.N., Gales A.C., and Sader H.S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother 52 (2003) 140-141
18. Karlowsky J.A., Jones M.E., Thornsberry C., Evangelista A.T., Yee Y.C., and Sahm D.F. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 Tracking Resistance in the United States Today surveillance studies. Clin Infect Dis 40 suppl 2 (2005) S89-S98
19. Landman D., Bratu S., Alam M., and Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 55 (2005) 954-957
20. Trouillet J.L., Vuagnat A., Combes A., Kassis N., Chastre J., and Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34 (2002) 1047-1054
21. Courvalin P., and Trieu-Cuot P. Minimizing potential resistance: the molecular view. Clin Infect Dis 33 suppl 3 (2001) S138-S146
22. Kriengkauykiat J., Porter E., Lomovskaya O., and Wong-Beringer A. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 565-570
23. Le Thomas I., Couetdic G., Clermont O., Brahimi N., Plesiat P., and Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 48 (2001) 553-555
24. Nakajima A., Sugimoto Y., Yoneyama H., and Nakae T. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol Immunol 46 (2002) 391-395
25. Higgins P.G., Fluit A.C., Milatovic D., Verhoef J., and Schmitz F.J. Mutations in GyrA, ParC, MexR, and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 21 (2003) 409-413
26. Zhang L., Li X.Z., and Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. J Antimicrob Chemother 48 (2001) 549-552
27. Giamarellou H., and Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am 85 (2001) 19-42 v
28. GF Weldhagen, L Poirel, P Nordmann. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003;47:2385-92.
29. Jones R.N., Biedenbach D.J., Sader H.S., Fritsche T.R., Toleman M.A., and Walsh T.R. Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis 51 (2005) 77-84
30. Fritsche T.R., Sader H.S., Toleman M.A., Walsh T.R., and Jones R.N. Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis 41 suppl 4 (2005) S276-S278
31. Watanabe M., Iyobe S., Inoue M., and Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35 (1991) 147-151
32. Peleg A.Y., Franklin C., Bell J., and Spelman D.W. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 54 (2004) 699-700
33. Lee K., Ha G.Y., Shin B.M., et al. Metallo-beta-lactamase-producing gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis 50 (2004) 51-58
34. Yan J.J., Hsueh P.R., Ko W.C., et al. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 45 (2001) 2224-2228
35. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 479-487
36. Cosgrove S.E., and Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 36 (2003) 1433-1437
37. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49 (2005) 760-766
38. Hyle E.P., Lipworth A.D., Zaoutis T.E., Nachamkin I., Bilker W.B., and Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 165 (2005) 1375-1380
39. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
40. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
41. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., and Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 (2005) 1306-1311
42. Hsu D.I., Okamoto M.P., Murthy R., and Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55 (2005) 535-541
43. Michalopoulos A., Kasiakou S.K., Mastora Z., Rellos K., Kapaskelis A.M., and Falagas M.E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 9 (2005) R53-R59
44. Ouderkirk J.P., Nord J.A., Turett G.S., and Kislak J.W. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 47 (2003) 2659-2662
45. Katragkou A., and Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 43 (2005) 4916-4917
46. McGowan Jr. J.E. Economic impact of antimicrobial resistance. Emerg Infect Dis 7 (2001) 286-292
47. Harrison P.F., and Lederberg J. Institute of Medicine. Antimicrobial Drug Resistance: Issues and Options. Institute of Medicine Workshop Report (1998), National Academy Press, Washington, DC. http://www.iom.edu/CMS/3783/3924/4564.aspx Accessed July 22, 2005
48. Wilson S.J., Knipe C.J., Zieger M.J., et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control 32 (2004) 342-344
49. Jones RN, Fritsche TR, for the CAP-MRC Members. Accuracy for antibacterial and antifungal susceptibility tests: report from the College of American Pathologists (CAP) Microbiology Proficiency Survey Program for 2004-2005. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC; 2005.
50. Swenson J.M., Killgore G.E., and Tenover F.C. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol 42 (2004) 5102-5108
51. Jain R., and Danziger L.H. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38 (2004) 1449-1459
52. Ferreira A.C., Gobara S., Costa S.E., et al. Emergence of resistance in Pseudomonas aeruginosa and Acinetobacter species after the use of antimicrobials for burned patients. Infect Control Hosp Epidemiol 25 (2004) 868-872
53. Harbarth S., and Samore M.H. Antimicrobial resistance determinants and future control. Emerg Infect Dis 11 (2005) 794-801
54. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., and Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289 (2003) 885-888
55. Villers D., Espaze E., Coste-Burel M., et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 129 (1998) 182-189
56. Leroy O., d'Escrivan T., Devos P., Dubreuil L., Kipnis E., and Georges H. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 33 (2005) 129-135
57. Paramythiotou E., Lucet J.C., Timsit J.F., et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 38 (2004) 670-677
58. McGowan Jr. J.E., and Tenover F.C. Control of antimicrobial resistance in the health care system. Infect Dis Clin North Am 11 (1997) 297-311
59. Pitout J.D., Gregson D.B., Poirel L., McClure J.A., Le P., and Church D.L. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 43 (2005) 3129-3135
60. Toleman M.A., Rolston K., Jones R.N., and Walsh T.R. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 48 (2004) 32-32
61. Spellberg B., Powers J.H., Brass E.P., Miller L.G., and Edwards Jr. J.E. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38 (2004) 1279-1286
62. McGowan Jr. J.E. Minimizing antimicrobial resistance: the key role of the infectious diseases physician. Clin Infect Dis 38 (2004) 939-942